San Diego, Calif – June 9, 2020 — Crown Bioscience today announced the presentation of new, proprietary NAFLD/NASH preclinical model development data. The data will be available at the American Diabetes Association (ADA) 80th Scientific Sessions, as well as CrownBio’s own complementary virtual event.
The new data shares development of NAFLD/NASH models generated through dietary modifications across CrownBio’s repertoire of highly translational rodent and NHP preclinical models. The models will enable enhanced preclinical NAFLD/NASH drug development, a disease area currently lacking approved therapies.
Alongside ADA 2020 posters, CrownBio is also supporting the concurrent International NASH Day on June 12th with a NAFLD/NASH model development presentation. CrownBio is hosting a free virtual event, providing access to all of these resources, which is registered for at CrownBio.com/ADA20.
“We’re committed to furthering and accelerating NAFLD/NASH research, by continuing to enhance our platform of highly translational preclinical models” said Dr. Jim Wang, senior vice president of cardiovascular and metabolic disease at CrownBio. “We’re delighted to be able to share our latest research in this area of high unmet need across a range of innovative virtual events this June”.
CrownBio’s virtual ADA event occurs from June 12th to 16th at CrownBio.com/ADA20, and will allow discussion with the CrownBio cardiovascular and metabolic disease team, as well as the review and download of a wide range of resources across disease areas including NAFLD/NASH, diabetes, obesity, renal and cardiovascular diseases.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit www.crownbio.com.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Appoints John Gu as Chief Executive Officer
Crown Bioscience appoints John Gu as CEO, leveraging his expertise in AI-driven drug discovery to advance biotechnological innovation and global health.
Crown Bioscience Completes Merger with Indivumed Services
Crown Bioscience completes Indivumed Services merger, offering enhanced drug development solutions globally and retiring the Indivumed brand.
Crown Bioscience Germany GmbH Achieves Continued CAP 15189:2022 Accreditation
Crown Bioscience's Hamburg site secures continued CAP ISO 15189:2022 accreditation, showcasing its commitment to quality in laboratory services.
Crown Bioscience Wins 2024 Fierce CRO Award for Excellence in Client Service and Partnership
Crown Bioscience wins 2024 Fierce CRO Award for excellence in client service, underscoring its commitment to innovative drug development partnerships.
Crown Bioscience Wins BioTech Breakthrough Award for Drug Development Innovation
Crown Bioscience's OrganoidXplore receives BioTech Award, revolutionizing oncology with advanced preclinical screening.